Molecular profiling, prognosis and present Guidelines for Relapsed/Refractory AML

Date 29 September 2019
Event ESMO 2019 Congress
Session ESMO Colloquium supported by Daiichi Sankyo Europe GmbH - Relapsed/Refractory FLT3-ITD mutated Acute Myeloid Leukemias (AML)
Topics Leukaemia
Anticancer Agents
Basic Scientific Principles
Personalised/Precision Medicine
Immunotherapy
Cancer Biology
Translational Research
Pathology/Molecular Biology
Basic Principles in the Management and Treatment (of cancer)
Therapy
Presenter Lars Bullinger
Authors L. Bullinger
  • Universitätsklinik Charité, Campus Virchow Klinikum, 13353 - Berlin/DE